EarningsQ2 2026 Earnings Report

Omnicell (OMCL) Q2 2026 Earnings Report

0 Followers

Previous Report: Q1 2026

MX:OMCL Q2 2026 EPS Results

Actual EPS$16.01

Consensus EPS$7.97

Beat/MissBeat by +$8.04

One Year Ago EPS$7.67

MX:OMCL Q2 2026 Revenue Results

Actual Revenue$5.32B

Expected Revenue$5.28B

Beat/MissBeat by +$33.98M

YoY Revenue Growth+7.45%

Earnings Announcement Details

QuarterQ2 2026

Date07/30/2026

TimeBefore Open

Conference CallThursday, July 30, 2026

MX:OMCL Upcoming Earnings

Omnicell's next earnings date is estimated for November 4, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:OMCL Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Jul 30, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents solid operating and financial execution in Q2 — revenue at the high end of guidance, strong cash generation, several strategic product wins and a materially larger pipeline — coupled with raised full-year profitability targets. However, key near-term risks include timing uncertainty around large product bookings (broad bookings range), a one-time tariff refund that boosted Q2 results, memory chip cost pressures (~$6M impact, ~50–80 bps margin effect), and slower consumables/ARR timing. Overall, the tone balances strong execution and long-term opportunity against near-term timing and supply-chain headwinds.

Company Guidance

Omnicell’s guidance for Q3 2026 is total revenue $301–307M, product revenue $169–172M, service revenue $132–135M, non‑GAAP EBITDA $32–37M and non‑GAAP EPS $0.35–0.43 (assuming ~18% non‑GAAP tax rate); the company reminded listeners Q2 results were $312M total revenue (product $175M, services $137M) with non‑GAAP EBITDA $67M (would have been $52M excl. a $15M tariff refund), non‑GAAP EPS $0.94, GAAP EPS $0.52, cash $292M and free cash flow $56M. For full‑year 2026 Omnicell updated guidance to product bookings $425–560M, total revenue $1.225–1.245B, product revenue $690–700M, service revenue $535–545M, year‑end ARR $660–680M, non‑GAAP EBITDA $175–185M and non‑GAAP EPS $2.15–2.30, while flagging a ~$6M incremental H2 memory‑cost headwind (~50 bps consolidated gross‑margin and ~80 bps product gross‑margin impact) and saying the wider bookings range reflects timing uncertainty rather than weaker demand.

Revenue at Top of Guidance

Total revenue of $312.0M in Q2 2026, reported at the high end of prior guidance, driven by product revenue of $175M and service revenue of $137M.

Strong Profitability and EPS Outperformance

Non-GAAP EBITDA of $67M and non-GAAP EPS of $0.94 came in well above prior outlooks; GAAP EPS was $0.52 versus $0.12 in the prior-year quarter (approximately +333% year-over-year).

Solid Cash Generation and Liquidity

Ended the quarter with $292M in cash and cash equivalents and generated $56M of free cash flow in Q2, supporting investment and expanded leasing programs.

Pipeline Expansion and Competitive Wins

Management reported a materially larger product bookings pipeline exiting Q2 than in recent years, including the first competitive Titan XT conversion win, multiple Titan XT selections across academic and regional health systems, a specialty pharmacy greenfield win (largest provider in Northwest Arizona), and two new specialty pharmacy engagements in Oregon and Missouri.

Progress on Product Roadmap and Timing

Titan XT remains on track for availability to ship in H2 2026, and OmniSphere ADS remains on track for general availability in H1 2027 — positioning the company for platform-driven enterprise opportunities.

Updated Full-Year Guidance with Improved Profitability

Full-year 2026 guidance: total revenue $1.225B–$1.245B, product revenue $690M–$700M, service revenue $535M–$545M, year-end ARR $660M–$680M, and non-GAAP EBITDA raised to $175M–$185M with non-GAAP EPS $2.15–$2.30.

MX:OMCL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 04, 2026	2026 (Q3)	7.12 / -	8.688	―
Jul 30, 2026	2026 (Q2)	7.97 / 16.01	7.665	108.89% (+8.35)
Apr 28, 2026	2026 (Q1)	5.64 / 9.37	4.429	111.54% (+4.94)
Feb 05, 2026	2025 (Q4)	8.45 / 6.81	10.221	-33.33% (-3.41)
Oct 30, 2025	2025 (Q3)	6.17 / 8.69	9.539	-8.93% (-0.85)
Jul 31, 2025	2025 (Q2)	4.60 / 7.67	8.688	-11.76% (-1.02)
May 06, 2025	2025 (Q1)	3.49 / 4.43	0.511	766.67% (+3.92)
Feb 06, 2025	2024 (Q4)	9.95 / 10.22	5.621	81.82% (+4.60)
Oct 30, 2024	2024 (Q3)	7.14 / 9.54	10.561	-9.68% (-1.02)
Aug 01, 2024	2024 (Q2)	2.45 / 8.69	9.71	-10.53% (-1.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed